We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Maternal Lipid Profile Tied to Pediatric CHD Risk

By LabMedica International staff writers
Posted on 25 Sep 2021
Congenital heart disease (CHD among live births, is the major form of birth defect and the leading cause of childhood mortality with an incidence of 9.1‰. More...
The occurrence of CHD is caused by many factors.

With the improvement in living standards and an increasing number of women with advanced maternal age, there is an increase in the prevalence of chronic metabolic diseases, such as obesity, diabetes, hypertension, and hyperlipidemia, among pregnant women.

Clinical Scientists at the Children's Hospital of Fudan University (Shanghai, China) carried out a single-center case–control study that included 230 mothers of offspring with CHD and 381 without CHD. Maternal lipid levels were determined on fasting blood samples taken in the first trimester. Relevant demographic and clinical data were extracted from the medical records. Maternal lipid profile was compared between the two groups, and regression analysis was performed to evaluate the association between lipid profile and CHD risk in offspring.

Fasting peripheral blood samples were collected between eight and 14 weeks of gestation. Folic acid, vitamin B12, thyroid abnormality, homocysteine (Hcy), triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), free fatty acid, Apolipoprotein-A1 (Apo-A1), Apolipoprotein-B (Apo-B), fasting blood glucose, and hemoglobin A1c (HbA1c) were all measured. TG, TC, HDL-C, LDL-C, free fatty acid, Apo-A1, Apo-B, and fasting blood glucose were analyzed by an automatic biochemical analyzer (Hitachi 7180, Tokyo, Japan) using commercially available kits. Folic acid and vitamin B12 were measured using the Architect i2000chemiluminescence immunoassay analyzer (Abbott, Lake Forest, IL, USA). Serum Hcy measurements were carried out by Liquid Chromatography Coupled to Tandem Mass Spectrometry (LC/MS/MS) using an API 3000 LC/MS/MS system (Applied Biosystems, Waltham, MA, USA).

The investigators reported that compared with the control group, levels of triglyceride, apolipoprotein-A1, and apolipoprotein-B in early pregnancy were significantly higher in the CHD group. Multivariate analyses showed that triglyceride (odds ratio [OR] 2.46), total/high-density lipoprotein cholesterol (OR 2.10), and apolipoprotein-A1 (OR 2.73), were positively associated with CHD risk in offspring. Each lipid biomarker was associated with an almost twofold increased risk of CHD, independent of HbA1c and Hcy.

The authors concluded that mild dyslipidemia in early pregnancy was closely associated with the occurrence of CHD in offspring. In combination with previous studies, it is possible that lipid metabolism in early pregnancy may influence the outcome of pregnancy. The study was published on August 3,2021 in the journal Acta Obstetricia et Gynecologica Scandinavica.

Related Links:

Children's Hospital of Fudan University
Hitachi 
Abbott
Applied Biosystems


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.